Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsJames B. Yu, MD, MHS, FASTRO
About
Copy Link
Titles
Assistant Professor Adjunct
Biography
James Yu, MD, MHS, is Professor of Radiation Oncology and Genitourinary Cancers Radiotherapy Lead at Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire.
He is a former Professor of Radiation Oncology at the Yale School of Medicine, former Associate Chief Medical Officer of the Smilow Cancer Hospital and Care Centers and Executive Vice Chair of Columbia University Irving Medical Center Department of Radiation Oncology.
In his academic work, Dr. Yu conducts research on ways to use radiotherapy treatments to improve outcomes for cancer patients. “We need to push the field ever forward and not be satisfied with merely prolonging survival,” says Dr. Yu. “I think radiosurgery will play a role in this. As systemic therapies improve and our ability to control microscopically disseminated disease improves, noninvasive ablative therapies will become ever more important.”
As a former Yale Center for Clinical Investigation scholar and founding member of the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale, Dr. Yu’s research centers on the comparative effectiveness of new radiation technologies and how these new technologies are adopted nationally.
Dr. Yu is the Editor-in Chief of JNCI Cancer Spectrum, Deputy Editor-In-Chief of the journal Practical Radiation Oncology and is on the editorial boards of the Journal of Clinical Oncology - Clinical Cancer Informatics, JNCI, Journal of Surgical Oncology, and Oncology (Williston Park), and former editorial board member of the Journal of Clinical Oncology.
He has published over 350 original manuscripts and co-edited the textbook Pocket Radiation Oncology and Principles of Clinical Cancer Research. He is the radiation oncology co-chair for the Southwest Oncology Group Genitourinary Cancers Committee, and a nationally recognized expert in patient reported outcomes.
Appointments
Medical Oncology and Hematology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- Brain Tumor Center
- COPPER Center
- Gamma Knife Center
- Internal Medicine
- Medical Oncology and Hematology
- Pituitary Program
- Prostate & Urologic Cancers Program
- Radiation Oncology
- Yale Cancer Center
- Yale Ventures
- Yale-BI Biomedical Data Science Fellowship
Education & Training
- MHS
- Yale University, Masters of Health Science (2014)
- Resident
- Yale New Haven Hospital (2009)
- Chief Resident
- Yale School of Medicine (2009)
- MD
- University of Michigan Medical School (2004)
- BS
- Yale University (1999)
Research
Copy Link
Overview
Medical Research Interests
ORCID
0000-0002-3119-3226
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Henry S. Park, MD, MPH
Veronica Chiang, MD, FAANS
Cary P Gross, MD
Sanjay Aneja, MD
Jeph Herrin, PhD
Victor Lee, MD
Breast Neoplasms
Radiotherapy, Intensity-Modulated
Head and Neck Neoplasms
Publications
2026
Diversity, equity, and inclusion as scientific rigor: progress during challenging times
Nogueira L, Hudson M, Pistilli B, Hochster H, Ambs S, Stockler M, Yu J, Franco E. Diversity, equity, and inclusion as scientific rigor: progress during challenging times. Journal Of The National Cancer Institute 2026, djag066. PMID: 42257610, DOI: 10.1093/jnci/djag066.Peer-Reviewed Original ResearchAltmetricAssociation between physician characteristics and likelihood of caring for underserved patients with cancer.
Roberts W, Soulos P, Herrin J, Long J, Genao I, Pollack C, Yu J, Boatright D, Gross C. Association between physician characteristics and likelihood of caring for underserved patients with cancer. Journal Of Clinical Oncology 2026, 44: 1646-1646. DOI: 10.1200/jco.2026.44.16_suppl.1646.Peer-Reviewed Original ResearchConceptsForeign-born physiciansCountry of birthDual eligiblesUnderserved patientsCancer physiciansPhysician raceMedicare beneficiariesUnderserved cancer patientsLow-income patientsMedicaid dual eligibilityDual-eligible patientsForeign-born statusPhysician race/ethnicityPhysician workforceHispanic physiciansRural patientsPhysician characteristicsOncology workforceBlack physiciansSEER-MedicareAsian physiciansPhysiciansBlack patientsAverage physicianWorkforceDiversity, equity, and inclusion as scientific rigor: progress during challenging times
Nogueira L, Hudson M, Pistilli B, Hochster H, Ambs S, Stockler M, Yu J, Franco E. Diversity, equity, and inclusion as scientific rigor: progress during challenging times. JNCI Cancer Spectrum 2026, 10: pkag046. PMID: 42257977, PMCID: PMC13244791, DOI: 10.1093/jncics/pkag046.Peer-Reviewed Original ResearchProstate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer
Leapman M, Rothen J, Long J, Kim I, Mitchell A, Yu J, Dinan M, Gross C, Ma X. Prostate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer. JAMA Oncology 2026, 12 PMID: 42096231, PMCID: PMC13154023, DOI: 10.1001/jamaoncol.2026.0893.Peer-Reviewed Original ResearchThis study investigates how PSMA-PET imaging for prostate cancer leads to earlier use of advanced therapies compared to traditional bone scans, impacting treatment decisions and costs.IP80-11 ASSOCIATION BETWEEN PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING AND INITIAL TREATMENT FOR PROSTATE CANCER AMONG COMMERCIAL INSURANCE BENEFICIARIES
Leapman M, Rothen J, Long J, Kim I, Mitchell A, Yu J, Dinan M, Gross C, Ma X. IP80-11 ASSOCIATION BETWEEN PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING AND INITIAL TREATMENT FOR PROSTATE CANCER AMONG COMMERCIAL INSURANCE BENEFICIARIES. Journal Of Urology 2026, 215: e1589. DOI: 10.1097/01.ju.0001191764.50307.1e.11.Peer-Reviewed Original ResearchCounty-Level Structural Racism Indices and Racial Disparities in Lung Cancer Care
Gaddy J, Lee D, Herrin J, Yu J, Pollack C, Dean L, Dougherty G, Canavan M, Soulos P, Gross C. County-Level Structural Racism Indices and Racial Disparities in Lung Cancer Care. JAMA Network Open 2026, 9: e2613919. PMID: 42160049, PMCID: PMC13191378, DOI: 10.1001/jamanetworkopen.2026.13919.Peer-Reviewed Original ResearchThis study investigates how structural racism at the county level impacts racial disparities in lung cancer care, showing worse outcomes for Black patients compared to white patients, especially in areas with higher structural racism.Treatment-Free Survival: A Novel Endpoint in Trials of Stereotactic Body Radiation With or Without Systemic Therapy
Einstein D, Chen R, Hoffman K, Madan R, Marvaso G, Tang C, Tran P, Yu J, Regan M. Treatment-Free Survival: A Novel Endpoint in Trials of Stereotactic Body Radiation With or Without Systemic Therapy. International Journal Of Radiation Oncology • Biology • Physics 2026, 125: 40-43. PMID: 42000365, DOI: 10.1016/j.ijrobp.2025.11.006.Peer-Reviewed Original ResearchAltmetricIn Reply to Shaffer et al
Yu J, Grew D, Spraker M, Beckta J, Shah C, Brower J. In Reply to Shaffer et al. Practical Radiation Oncology 2026, 16: 320. PMID: 42103411, DOI: 10.1016/j.prro.2025.10.016.Peer-Reviewed Original ResearchFactors Associated With Rectal Spacer Use in Prostate Cancer Patients Receiving Radiation Therapy
Hankins R, Morris K, McGovern A, Zack J, Collins S, Yu J. Factors Associated With Rectal Spacer Use in Prostate Cancer Patients Receiving Radiation Therapy. Cancer Medicine 2026, 15: e71765. PMID: 42046879, PMCID: PMC13122126, DOI: 10.1002/cam4.71765.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsStereotactic body radiationIntensity-modulated radiotherapyProstate cancerRectal spacerRadiation therapySpacer useProton therapyMen treated with radiation therapyProportion of white patientsRadiation therapy modalitiesProstate cancer patientsProton therapy patientsMedicare 5% Standard Analytic FilesCancer-related deathsTreatment-related factorsStandard Analytic FilesTherapy initiationTreatment modalitiesSpacer placementPre-radiationTherapy patientsCancer patientsWhite patientsProstateTherapy modalitiesEarly-Stage Lung Cancer Treatment Disparities by Race Among Medicare Beneficiaries
Lynch O, Lee D, Soulos P, Yu J, Herrin J, Gross C. Early-Stage Lung Cancer Treatment Disparities by Race Among Medicare Beneficiaries. JAMA Network Open 2026, 9: e2559845. PMID: 41770564, PMCID: PMC12954539, DOI: 10.1001/jamanetworkopen.2025.59845.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMedicare beneficiariesRacial disparitiesStereotactic body radiotherapyWhite patientsBlack patientsNon-Hispanic white patientsEarly-stage NSCLCCancer treatment disparitiesLung cancer careCurative treatmentSEER-Medicare dataReceipt of surgeryCancer careSurgical treatmentDiagnosis of stage IRetrospective cohort studyMain OutcomesTreatment disparitiesSEER-MedicareCohort studyMedicareRacial differencesDisparitiesEnd ResultsAdjusted probability
Academic Achievements & Community Involvement
Copy Link
Honors
honor Fellow
07/17/2023National AwardAmerican Society for Radiation OncologyDetailsUnited Stateshonor Cancer Prevention and Control Research Prize
12/31/2017Yale School of Medicine AwardYale Cancer CenterDetailsUnited Stateshonor Population Research Prize
11/22/2013Yale School of Medicine AwardYale Cancer CenterDetailsUnited Stateshonor Seattle Prostate Brachytherapy Fellow
01/01/2009National AwardAmerican Brachytherapy SocietyDetailsUnited Stateshonor Young Oncologist Essay Award
01/01/2008National AwardAmerican Radium SocietyDetailsUnited States
News
Copy Link
News
Get In Touch
Copy Link